![]() | |
Clinical data | |
---|---|
Other names | APX001, APX-001 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C22H21N4O6P |
Molar mass | 468.406 g·mol−1 |
3D model ( JSmol) | |
| |
|
Fosmanogepix is an experimental antifungal drug being developed by Amplyx Pharmaceuticals (now currently by Pfizer and Basilea [1] [2]) It is being investigated for its potential to treat various fungal infections including aspergillosis, candidaemia, and coccidioidomycosis. [3]
Fosmanogepix is a prodrug and is converted into the active drug form, manogepix in vivo. [4] Manogepix targets the enzyme GWT1 (Glycosylphosphatidylinositol-anchored Wall protein Transfer 1 [5]), an enzyme in the glycosylphosphatidylinositol biosynthesis pathway. [6] Inhibiting this enzyme prevents the fungi from properly modifying certain (so called GPI-anchored) proteins essential to the fungal life cycle. This mechanism of action is totally novel; therefore, if approved, fosmanogepix would become a first-in-class medication. [6] [7]
In 2023, the drug was given a compassionate use authorization for four patients with Fusarium solani meningitis. [8]
![]() | |
Clinical data | |
---|---|
Other names | APX001, APX-001 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C22H21N4O6P |
Molar mass | 468.406 g·mol−1 |
3D model ( JSmol) | |
| |
|
Fosmanogepix is an experimental antifungal drug being developed by Amplyx Pharmaceuticals (now currently by Pfizer and Basilea [1] [2]) It is being investigated for its potential to treat various fungal infections including aspergillosis, candidaemia, and coccidioidomycosis. [3]
Fosmanogepix is a prodrug and is converted into the active drug form, manogepix in vivo. [4] Manogepix targets the enzyme GWT1 (Glycosylphosphatidylinositol-anchored Wall protein Transfer 1 [5]), an enzyme in the glycosylphosphatidylinositol biosynthesis pathway. [6] Inhibiting this enzyme prevents the fungi from properly modifying certain (so called GPI-anchored) proteins essential to the fungal life cycle. This mechanism of action is totally novel; therefore, if approved, fosmanogepix would become a first-in-class medication. [6] [7]
In 2023, the drug was given a compassionate use authorization for four patients with Fusarium solani meningitis. [8]